Bowel surgery death rate 'too high'

Bowel surgery death rate warning

  • 30 June 2015
  • From the section Health

Too many patients are dying following emergency bowel surgery, experts who have done a comprehensive audit of care across England and Wales warn.

One in 10 patients dies within 30 days of undergoing urgent, unplanned laparotomy and some of these deaths could be avoided, the authors say.

The National Emergency Laparotomy Audit team found the care for these high-risk patients was lacking at some hospitals.

Expert supervision and best treatment was not always immediately on hand.

Families speak out over Tawel Fan

Tawel Fan families speak out for first time over care

  • 30 June 2015
  • From the section North East Wales

Families have spoken out for the first time about the “deplorable” care their loved ones received at a Denbighshire mental health ward.

The damning report into the Tawel Fan ward at Glan Clwyd Hospital revealed patients were “kept like animals”.

Three families told BBC Wales’ Week In Week Out about their despair and shock at the brutality of care on the ward.

Betsi Cadwaladr University Health Board chairman Dr Peter Higson said the ward will never be used again.

Novartis to test new pricing model with heart failure drug

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013. REUTERS/Arnd Wiegmann

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.

Reuters/Arnd Wiegmann

Novartis plans to test a novel pricing model with some customers when it launches its keenly awaited new heart failure drug Entresto, the Swiss company’s head of pharmaceuticals said on Tuesday.

Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. As a result, it is widely expected to generate billions of dollars in annual sales.

Liberia records Ebola death after country declared virus-free

A health worker injects a woman with an Ebola vaccine during a trial in Monrovia, February 2, 2015. REUTERS/James Giahyue

A health worker injects a woman with an Ebola vaccine during a trial in Monrovia, February 2, 2015.

Reuters/James Giahyue

A Liberian has died of Ebola in the first recorded case of the disease since a country at the heart of an epidemic that has killed more than 11,000 people was declared virus-free on May 9 after going 42 days without a new case.

Overused Antibiotics Cause Havoc Among Nursing Home Patients

Action Points

  • Note that this study of antibiotic use in nursing homes found that nursing homes in the highest tertile of use also had higher rates of adverse events.
  • Be aware that, though adjustments for case-mix were performed, it is conceivable that some of this result is due to confounding by the fact that some nursing homes cater to sicker patients.

One in eight nursing home residents experienced an adverse event related to antibiotic prescribing, regardless of whether they personally took the antibiotics, researchers reported.

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.

Diabetes Drug Found Useless for Parkinson's

Action Points

  • Note that this trial of two doses of pioglitazone showed no effect compared with placebo in patients with Parkinson’s disease.
  • Be aware that animal studies that suggested this might be efficacious were conducted in toxin-induced Parkinson’s models.

The diabetes drug pioglitazone (Actos) isn’t likely to slow the progression of early Parkinson’s disease, researchers reported.

A futility study showed in several analyses that both doses of the drug that were tested (15 mg and 45 mg) were futile at slowing disease progression, Tanya Simuni, MD, of Northwestern University, and colleagues reported online in the Lancet Neurology.

NHS wants negligence legal costs capped

Medical legal costs ‘excessive and should be capped’

  • 28 June 2015
  • From the section Health
Medical negligence claims are rising

The government intends to put strict limits on the “excessive fees” some lawyers claim in medical negligence cases against the NHS in England.

Officials want a defined limit on legal costs in cases where the claims are below £100,000, saying that some lawyers submit bills that charge more than patients receive in compensation.

But solicitors warn the move could deny patients access to justice.

Figures show the NHS was charged £259m in legal fees for claims in 2013-14.

Meet the New Acting Administrator – First 100 Days, 6 Questions with Andy Slavitt

Meet the New Acting Administrator – First 100 Days, 6 Questions with Andy Slavitt

June 26

Earlier this year, Andy Slavitt was named Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). As Acting Administrator, Andy oversees programs that provide access to health care for 140 million Americans, including Medicaid, Medicare, the Children’s Health Insurance Program, and the Health Insurance Marketplace. 

1. You’ve been at CMS 100 days. Tell us about how you’ve spent your time. 

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline. Updates are being presented today at its R&D Day for analysts and investors in New York, NY.